Sanofi (SNY)
(Real Time Quote from BATS)
$56.34 USD
+0.02 (0.04%)
Updated Aug 28, 2024 11:02 AM ET
3-Hold of 5 3
A Value C Growth B Momentum A VGM
Company Summary
Sanofi, located in Paris, France, manufactures and markets prescription drugs in Europe, the United States and other countries. It focuses on major therapeutic areas such as immunology, neurology, oncology, rare disease, rare blood disorders and diabetes, among others.
In April 2011, Genzyme Corporation became a subsidiary of Sanofi. The deal added products like Cerezyme, Myozyme/Lumizyme and Fabrazyme in its portfolio. Sanofi swapped its Merial Animal Health businesses with Boehringer Ingelheim’s Consumer Healthcare (CHC) business in January 2017. With the acquisition of Chattem in 2010, Sanofi became a major player in the CHC sector. ...
Company Summary
Sanofi, located in Paris, France, manufactures and markets prescription drugs in Europe, the United States and other countries. It focuses on major therapeutic areas such as immunology, neurology, oncology, rare disease, rare blood disorders and diabetes, among others.
In April 2011, Genzyme Corporation became a subsidiary of Sanofi. The deal added products like Cerezyme, Myozyme/Lumizyme and Fabrazyme in its portfolio. Sanofi swapped its Merial Animal Health businesses with Boehringer Ingelheim’s Consumer Healthcare (CHC) business in January 2017. With the acquisition of Chattem in 2010, Sanofi became a major player in the CHC sector. Other smaller acquisitions in the past few years include Ablynx and Bioverativ in 2018, Synthorx and Principia in 2020, Translate Bio and Kadmon in 2021, Provention Bio in 2023 and Inhibrx in 2024.
Sanofi has collaboration agreements with companies like Regeneron among others. Sanofi has developed and markets Dupixent and Kevzara in collaboration with Regeneron. Initially the companies also co-marketed Praluent and Libtayo. However, from April 2020, the agreement was restructured. Sanofi is now solely responsible for Praluent marketing in outside U.S. markets while Regeneron has the sole responsibility for Praluent in the United States. In 2022, Sanofi also restructured its immuno-oncology collaboration with Regeneron regarding Libtayo by granting them the worldwide exclusive license rights of the drug.
Sanofi’s Biopharma segment now comprises Pharma and Vaccines. Till 2023, it comprised three operating segments: Specialty Care (Dupixent, neurology & immunology, rare diseases, rare blood disorders, and oncology), Vaccines and General Medicines (diabetes, cardiovascular, and established products). The company’s Consumer Healthcare (CHC) was established as a standalone business unit in 2019. In October 2023, Sanofi announced that it intends to separate the CHC unit through the creation of a publicly-listed entity headquartered in Paris to be called Opella. The separation is expected to be completed by late 2024 or early 2025.
In 2023, total sales rose 5.4% (at CER) to €43.0 billion. Specialty Care accounted for 41.9% while General Medicines accounted for 28.7% of the company’s total sales. Vaccines accounted for 17.3% of total sales. The CHC unit accounted for 12.1% of 2023 total sales.
General Information
Sanofi
46 AVENUE DE LA GRANDE ARMEE
PARIS, I0 75017
Phone: 33-1-53-77-44-00
Fax: 33-1-53-77-43-03
Email: ir@sanofi.com
Industry | Large Cap Pharmaceuticals |
Sector | Medical |
Fiscal Year End | December |
Last Reported Quarter | 6/30/2024 |
Exp Earnings Date | 10/25/2024 |
EPS Information
Current Quarter EPS Consensus Estimate | 1.37 |
Current Year EPS Consensus Estimate | 4.23 |
Estimated Long-Term EPS Growth Rate | 8.30 |
Exp Earnings Date | 10/25/2024 |
Price and Volume Information
Zacks Rank | ![]() |
Yesterday's Close | 56.32 |
52 Week High | 56.57 |
52 Week Low | 42.63 |
Beta | 0.59 |
20 Day Moving Average | 1,628,300.75 |
Target Price Consensus | 62.30 |
4 Week | 8.96 |
12 Week | 14.45 |
YTD | 13.25 |
4 Week | 5.29 |
12 Week | 7.64 |
YTD | -3.98 |
Shares Outstanding (millions) | 2,532.73 |
Market Capitalization (millions) | 142,643.11 |
Short Ratio | NA |
Last Split Date | NA |
Dividend Yield | 2.63% |
Annual Dividend | $1.48 |
Payout Ratio | 0.35 |
Change in Payout Ratio | 0.02 |
Last Dividend Payout / Amount | NA / $0.00 |
Fundamental Ratios
P/E (F1) | 13.33 |
Trailing 12 Months | 13.51 |
PEG Ratio | 1.60 |
vs. Previous Year | -2.11% |
vs. Previous Quarter | -3.12% |
vs. Previous Year | 6.62% |
vs. Previous Quarter | 1.80% |
Price/Book | 1.81 |
Price/Cash Flow | 8.81 |
Price / Sales | 2.99 |
6/30/24 | 26.29 |
3/31/24 | 26.25 |
12/31/23 | 27.47 |
6/30/24 | 15.12 |
3/31/24 | 15.35 |
12/31/23 | 16.07 |
6/30/24 | 1.00 |
3/31/24 | NA |
12/31/23 | 1.27 |
6/30/24 | 0.65 |
3/31/24 | NA |
12/31/23 | 0.87 |
6/30/24 | 21.92 |
3/31/24 | 22.35 |
12/31/23 | 23.58 |
6/30/24 | 9.60 |
3/31/24 | 10.52 |
12/31/23 | 12.56 |
6/30/24 | 12.84 |
3/31/24 | 13.98 |
12/31/23 | 15.40 |
6/30/24 | 31.04 |
3/31/24 | NA |
12/31/23 | 31.81 |
6/30/24 | 2.91 |
3/31/24 | 2.97 |
12/31/23 | 2.89 |
6/30/24 | 0.17 |
3/31/24 | NA |
12/31/23 | 0.19 |
6/30/24 | 14.62 |
3/31/24 | NA |
12/31/23 | 16.17 |